bioMérieux Stock Rebounds by 3.5% and Moves Above Its MM50
bioMérieux stock sees a significant uptick in late afternoon trading, buoyed by a general rebound in the CAC 40 after several turbulent sessions. The Lyon-based company's stock is recovering after a heavily degraded quarter, although it remains significantly down over the year. Bank of America also adjusted its rating earlier in the week.
A Rebound That Takes the Stock Above Its Short-Term Moving Averages
bioMérieux stock gains 3.33% to €71.45, as it had lost ground the previous day and tested its MM20. The stock is among the top gainers in the SBF 120, with the index up by 0.61%. This session allows the stock price to move above its MM20 (€68.87) and MM50 (€70.79), with respective increases of +3.75% and +0.93%.
The 200-day moving average (€94.32) remains significantly distant, more than 24% above the current price, highlighting the extent of the underlying decline. Over one year, the stock is still down nearly 40% and shows a -22.88% over three months. The RSI at 48 indicates momentum has returned to a neutral zone after several weeks of selling pressure, while the resistance at €74.35 remains the next visible threshold on the chart.
BofA Securities Lowers Price Target to €80 Early in the Week
Alongside today's rebound, BofA Securities reduced its price target from €85 to €80 on July 7, while maintaining a 'hold' rating. The new target suggests a potential upside of about 12% from the current price. This adjustment follows the previous session, where the stock suffered from a deteriorated market environment.
The macroeconomic context continues to be marked by renewed tensions in the Middle East and a surge in Brent crude above $78, two factors that do not directly affect medical diagnostics but weigh on risk appetite in Europe. The next technical level to watch remains the resistance at €74.35, whose breach would condition the continuation of the rebound.
